FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136985> ?p ?o ?g. }

• W4324136985 endingPage "177" @default.
• W4324136985 startingPage "177" @default.
• W4324136985 abstract "177 Background: EPI-7386 is a next generation aniten, a novel class of compounds designed to inhibit androgen receptor (AR) activity by binding to the N-terminal domain. Preclinical data supports disruption of AR regulated gene transcription even in the presence of resistance mechanisms including ligand-binding domain point mutations and truncated splice variants. Here we report results of the Part 1a first-in-human trial of EPI-7386 in mCRPC (NCT04421222). Methods: This Phase 1, open-label, multicenter, dose escalation (Part 1a) and expansion (Part 1b) trial was designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of EPI-7386 in mCRPC patients (pts) progressing on standard of care treatment, including next generation antiandrogen(s) and chemotherapy. Originally designed to assess up to 5 doses of EPI-7386 (200, 400, 600, 800, and 1000 mg QD), two additional cohorts were added examining 400 and 600 mg BID due to 600 mg QD showing exposure saturation while demonstrating a favorable safety profile. Results: 31 pts were enrolled in the QD cohorts and 8 in the BID cohorts. Pts had a median of 4 lines of prior therapy for mCRPC: 83% received abiraterone and at least one next generation AR inhibitor, and 58% had at least one line of prior chemotherapy. No DLTs were observed; EPI-7386 was safe and well tolerated at all doses/schedules evaluated. All related adverse events (AEs) were Grade 1 and 2 and consistent with AEs associated with second-generation antiandrogens. For doses above 400 mg QD, exposures were at or above those associated with antitumor activity in animal models. Evidence of antitumor activity (including significant and durable PSA responses and/or decreases in ctDNA, and/or radiographically documented tumor shrinkage) were observed in pts with fewer than 3 lines of treatment for mCRPC, no visceral metastases and no prior chemotherapy (9/31 pts). Conclusions: Part 1a treatment with EPI-7386 monotherapy was safe, well tolerated up to a daily dose of 1200 mg (600 mg BID), achieved target clinical exposures and showed preliminary signals of antitumor activity in heavily-pretreated mCRPC. Part 1b is open with enrollment focused on pre-chemotherapy, post-second generation antiandrogen treated mCRPC pts in one cohort, and treatment-naïve non-mCRPC pts in a window of opportunity proof-of-concept second cohort. Two doses will be evaluated (600 mg BID and QD) based on FDA Project Optimus recommendations. Clinical trial information: NCT04421222 ." @default.
• W4324136985 created "2023-03-15" @default.
• W4324136985 creator A5001082720 @default.
• W4324136985 creator A5005231494 @default.
• W4324136985 creator A5017925159 @default.
• W4324136985 creator A5035665916 @default.
• W4324136985 creator A5049648936 @default.
• W4324136985 creator A5049918594 @default.
• W4324136985 creator A5050588157 @default.
• W4324136985 creator A5055207707 @default.
• W4324136985 creator A5059177030 @default.
• W4324136985 creator A5059219836 @default.
• W4324136985 creator A5072917229 @default.
• W4324136985 creator A5083027775 @default.
• W4324136985 creator A5089420153 @default.
• W4324136985 date "2023-02-20" @default.
• W4324136985 modified "2023-10-11" @default.
• W4324136985 title "Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer." @default.
• W4324136985 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.177" @default.
• W4324136985 hasPublicationYear "2023" @default.
• W4324136985 type Work @default.
• W4324136985 citedByCount "0" @default.
• W4324136985 crossrefType "journal-article" @default.
• W4324136985 hasAuthorship W4324136985A5001082720 @default.
• W4324136985 hasAuthorship W4324136985A5005231494 @default.
• W4324136985 hasAuthorship W4324136985A5017925159 @default.
• W4324136985 hasAuthorship W4324136985A5035665916 @default.
• W4324136985 hasAuthorship W4324136985A5049648936 @default.
• W4324136985 hasAuthorship W4324136985A5049918594 @default.
• W4324136985 hasAuthorship W4324136985A5050588157 @default.
• W4324136985 hasAuthorship W4324136985A5055207707 @default.
• W4324136985 hasAuthorship W4324136985A5059177030 @default.
• W4324136985 hasAuthorship W4324136985A5059219836 @default.
• W4324136985 hasAuthorship W4324136985A5072917229 @default.
• W4324136985 hasAuthorship W4324136985A5083027775 @default.
• W4324136985 hasAuthorship W4324136985A5089420153 @default.
• W4324136985 hasConcept C111113717 @default.
• W4324136985 hasConcept C112705442 @default.
• W4324136985 hasConcept C121608353 @default.
• W4324136985 hasConcept C126322002 @default.
• W4324136985 hasConcept C143998085 @default.
• W4324136985 hasConcept C197934379 @default.
• W4324136985 hasConcept C2775832370 @default.
• W4324136985 hasConcept C2776421732 @default.
• W4324136985 hasConcept C2776551883 @default.
• W4324136985 hasConcept C2777899217 @default.
• W4324136985 hasConcept C2778375690 @default.
• W4324136985 hasConcept C2779322244 @default.
• W4324136985 hasConcept C2780192828 @default.
• W4324136985 hasConcept C61367390 @default.
• W4324136985 hasConcept C71924100 @default.
• W4324136985 hasConcept C98274493 @default.
• W4324136985 hasConceptScore W4324136985C111113717 @default.
• W4324136985 hasConceptScore W4324136985C112705442 @default.
• W4324136985 hasConceptScore W4324136985C121608353 @default.
• W4324136985 hasConceptScore W4324136985C126322002 @default.
• W4324136985 hasConceptScore W4324136985C143998085 @default.
• W4324136985 hasConceptScore W4324136985C197934379 @default.
• W4324136985 hasConceptScore W4324136985C2775832370 @default.
• W4324136985 hasConceptScore W4324136985C2776421732 @default.
• W4324136985 hasConceptScore W4324136985C2776551883 @default.
• W4324136985 hasConceptScore W4324136985C2777899217 @default.
• W4324136985 hasConceptScore W4324136985C2778375690 @default.
• W4324136985 hasConceptScore W4324136985C2779322244 @default.
• W4324136985 hasConceptScore W4324136985C2780192828 @default.
• W4324136985 hasConceptScore W4324136985C61367390 @default.
• W4324136985 hasConceptScore W4324136985C71924100 @default.
• W4324136985 hasConceptScore W4324136985C98274493 @default.
• W4324136985 hasIssue "6_suppl" @default.
• W4324136985 hasLocation W43241369851 @default.
• W4324136985 hasOpenAccess W4324136985 @default.
• W4324136985 hasPrimaryLocation W43241369851 @default.
• W4324136985 hasRelatedWork W2205955695 @default.
• W4324136985 hasRelatedWork W2212015457 @default.
• W4324136985 hasRelatedWork W2783882412 @default.
• W4324136985 hasRelatedWork W2891081513 @default.
• W4324136985 hasRelatedWork W2891268463 @default.
• W4324136985 hasRelatedWork W2948798859 @default.
• W4324136985 hasRelatedWork W3156855168 @default.
• W4324136985 hasRelatedWork W3202359850 @default.
• W4324136985 hasRelatedWork W4225149097 @default.
• W4324136985 hasRelatedWork W4229076799 @default.
• W4324136985 hasVolume "41" @default.
• W4324136985 isParatext "false" @default.
• W4324136985 isRetracted "false" @default.
• W4324136985 workType "article" @default.